[1] KASSI E, SPILIOTI E, NASIRI-ANSARI N, et al. Vascular inflammation and atherosclerosis:the role of estrogen receptors[J]. Curr Med Chem, 2015, 22(22):2651-2665.
[2] MACLARAN K, STEVENSON J C.Primary prevention of cardiovascular disease with HRT[J]. Womens Health (Lond), 2012, 8(1):63-74.
[3] VAN KEEP P A.The history and rationale of hormone replacement therapy[J]. Maturitas, 1990, 12(3):163-170.
[4] ROSSOUW J E, ANDERSON G L, PRENTICE R L, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women:principal results from the women's health initiative randomized controlled trial [J]. Jama, 2002, 288(3):321-333.
[5] HODIS H N, MACK W J, HENDERSON V W, et al. Vascular effects of early versus late postmenopausal treatment with estradiol[J]. N Engl J Med, 2016, 374(13):1221-1231.
[6] GUSTAFSSON J A.What pharmacologists can learn from recent advances in estrogen signalling[J]. Trends Pharmacol Sci, 2003, 24(9):479-485.
[7] KUIPER G G, CARLSSON B, GRANDIEN K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta[J]. Endocrinology, 1997, 138(3):863-870.
[8] GRUBER D M, HUBER J C.Conjugated estrogens—the natural SERMs[J]. Gynecol Endocrinol, 1999, 13(Suppl 6):9-12.
[9] NILSSON S, MäKELä S, TREUTER E, et al. Mechanisms of estrogen action[J]. Physiol Rev, 2001, 81(4):1535-1565.
[10] ENMARK E, PELTO-HUIKKO M, GRANDIEN K, et al. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern[J]. J Clin Endocrinol Metab, 1997, 82(12):4258-4265.
[11] MENASCE L P, WHITE G R, HARRISON C J, et al. Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique[J]. Genomics, 1993, 17(1):263-265.
[12] FILARDO E J, QUINN J A, BLAND K I, et al. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF[J]. Mol Endocrinol, 2000, 14(10):1649-1660.
[13] FILARDO E J, THOMAS P.GPR30:a seven-transmembrane-spanning estrogen receptor that triggers EGF release[J]. Trends Endocrinol Metab, 2005, 16(8):362-367.
[14] PROSSNITZ E R, ARTERBURN J B, SMITH H O, et al. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30[J]. Annu Rev Physiol, 2008, 70:165-190.
[15] HALL J M, COUSE J F, KORACH K S.The multifaceted mechanisms of estradiol and estrogen receptor signaling[J]. J Biol Chem, 2001, 276(40):36869-36872.
[16] KUSHNER P J, AGARD D A, GREENE G L, et al. Estrogen receptor pathways to AP-1[J]. J Steroid Biochem Mol Biol, 2000, 74(5):311-317.
[17] SAVILLE B, WORMKE M, WANG F, et al. Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements[J]. J Biol Chem, 2000, 275(8):5379-5387.
[18] SIMONCINI T, MANNELLA P, FORNARI L, et al. Genomic and non-genomic effects of estrogens on endothelial cells[J]. Steroids, 2004, 69(8-9):537-542.
[19] WONG C W, MCNALLY C, NICKBARG E, et al. Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade[J]. Proc Natl Acad Sci U S A, 2002, 99(23):14783-14788.
[20] COLLINS P.Clinical cardiovascular studies of hormone replacement therapy[J]. Am J Cardiol, 2002, 90(1a):30f-34f.
[21] REN J, KELLEY R O.Cardiac health in women with metabolic syndrome:clinical aspects and pathophysiology [J]. Obesity (Silver Spring), 2009, 17(6):1114-1123.
[22] KAPLAN J R, MANUCK S B.Ovarian dysfunction and the premenopausal origins of coronary heart disease[J]. Menopause, 2008, 15(4 Pt 1):768-776.
[23] ARCHER D F.Premature menopause increases cardiovascular risk[J]. Climacteric, 2009, 12(Suppl 1):26-31.
[24] KANNEL W B, HJORTLAND M C, MCNAMARA P M, et al. Menopause and risk of cardiovascular disease:the Framingham study[J]. Ann Intern Med, 1976, 85(4):447-452.
[25] MAHMOODZADEH S, EDER S, NORDMEYER J, et al. Estrogen receptor alpha up-regulation and redistribution in human heart failure [J]. Faseb J, 2006, 20(7):926-934.
[26] TAYLOR A H, AL-AZZAWI F.Immunolocalisation of oestrogen receptor beta in human tissues[J]. J Mol Endocrinol, 2000, 24(1):145-155.
[27] KNOWLTON A A, LEE A R.Estrogen and the cardiovascular system[J]. Pharmacol Ther, 2012, 135(1):54-70.
[28] BOWLING M R, XING D, KAPADIA A, et al. Estrogen effects on vascular inflammation are age dependent:role of estrogen receptors[J]. Arterioscler Thromb Vasc Biol, 2014, 34(7):1477-1485.
[29] O'LONE R, KNORR K, JAFFE I Z, et al. Estrogen receptors alpha and beta mediate distinct pathways of vascular gene expression, including genes involved in mitochondrial electron transport and generation of reactive oxygen species[J]. Mol Endocrinol, 2007, 21(6):1281-1296.
[30] ZHAI P, EURELL T E, COOKE P S, et al. Myocardial ischemia-reperfusion injury in estrogen receptor-alpha knockout and wild-type mice[J]. Am J Physiol Heart Circ Physiol, 2000, 278(5):H1640-1647.
[31] RUBANYI G M, FREAY A D, KAUSER K, et al. Vascular estrogen receptors and endothelium-derived nitric oxide production in the mouse aorta.Gender difference and effect of estrogen receptor gene disruption[J]. J Clin Invest, 1997, 99(10):2429-2437.
[32] JOHNSON B D, ZHENG W, KORACH K S, et al. Increased expression of the cardiac L-type calcium channel in estrogen receptor-deficient mice[J]. J Gen Physiol, 1997, 110(2):135-140.
[33] SMITH E P, BOYD J, FRANK G R, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man[J]. N Engl J Med, 1994, 331(16):1056-1061.
[34] HEINE P A, TAYLOR J A, IWAMOTO G A, et al. Increased adipose tissue in male and female estrogen receptor-alpha knockout mice[J]. Proc Natl Acad Sci U S A, 2000, 97(23):12729-12734.
[35] OKURA T, KODA M, ANDO F, et al. Association of polymorphisms in the estrogen receptor alpha gene with body fat distribution[J]. Int J Obes Relat Metab Disord, 2003, 27(9):1020-1027.
[36] WANG M, CRISOSTOMO P, WAIRIUKO G M, et al. Estrogen receptor-alpha mediates acute myocardial protection in females[J]. Am J Physiol Heart Circ Physiol, 2006, 290(6):H2204-2209.
[37] ARIAS-LOZA P A, KREISSL M C, KNEITZ S, et al. The estrogen receptor-α is required and sufficient to maintain physiological glucose uptake in the mouse heart[J]. Hypertension, 2012, 60(4):1070-1077.
[38] DEVANATHAN S, WHITEHEAD T, SCHWEITZER G G, et al. An animal model with a cardiomyocyte-specific deletion of estrogen receptor alpha:functional, metabolic, and differential network analysis[J]. PLoS One, 2014, 9(7):e101900.
[39] MAHMOODZADEH S, LEBER J, ZHANG X, et al. Cardiomyocyte-specific estrogen receptor alpha increases angiogenesis, lymphangiogenesis and reduces fibrosis in the female mouse heart post-myocardial infarction[J]. J Cell Sci Ther, 2014, 5(1):153.
[40] PARE G, KRUST A, KARAS R H, et al. Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury[J]. Circ Res, 2002, 90(10):1087-1092.
[41] LOSORDO D W, KEARNEY M, KIM E A, et al. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women[J]. Circulation, 1994, 89(4):1501-1510.
[42] KARAS R H, HODGIN J B, KWOUN M, et al. Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice[J]. Proc Natl Acad Sci U S A, 1999, 96(26):15133-15136.
[43] ZHU Y, BIAN Z, LU P, et al. Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta[J]. Science, 2002, 295(5554):505-508.
[44] WANG M, WANG Y, WEIL B, et al. Estrogen receptor beta mediates increased activation of PI3K/Akt signaling and improved myocardial function in female hearts following acute ischemia[J]. Am J Physiol Regul Integr Comp Physiol, 2009, 296(4):R972-978.
[45] FORYST-LUDWIG A, CLEMENZ M, HOHMANN S, et al. Metabolic actions of estrogen receptor beta (ERbeta) are mediated by a negative cross-talk with PPARgamma[J]. PLoS Genet, 2008, 4(6):e1000108.
[46] CHRISTIAN R C, LIU P Y, HARRINGTON S, et al. Intimal estrogen receptor (ER)beta, but not ERalpha expression, is correlated with coronary calcification and atherosclerosis in pre-and postmenopausal women[J]. J Clin Endocrinol Metab, 2006, 91(7):2713-2720.
[47] LIZOTTE E, GRANDY S A, TREMBLAY A, et al. Expression, distribution and regulation of sex steroid hormone receptors in mouse heart[J]. Cell Physiol Biochem, 2009, 23(1-3):75-86.
[48] LUO T, KIM J K.The role of estrogen and estrogen receptors on cardiomyocytes:an overview[J]. Can J Cardiol, 2016, 32(8):1017-1025.
[49] DANTAS A P, FORTES Z B, DE CARVALHO M H.Vascular disease in diabetic women:why do they miss the female protection?[J]. Exp Diabetes Res, 2012, 2012:570598.
[50] NOVELLA S, HERAS M, HERMENEGILDO C, et al. Effects of estrogen on vascular inflammation:a matter of timing[J]. Arterioscler Thromb Vasc Biol, 2012, 32(8):2035-2042.
[51] PARK Y M, PEREIRA R I, ERICKSON C B, et al. Estradiol-mediated improvements in adipose tissue insulin sensitivity are related to the balance of adipose tissue estrogen receptor α and β in postmenopausal women[J]. PLoS One, 2017, 12(5):e0176446.
[52] MIRó A M, SASTRE-SERRA J, PONS D G, et al. 17β-Estradiol regulates oxidative stress in prostate cancer cell lines according to ERalpha/ERbeta ratio[J]. J Steroid Biochem Mol Biol, 2011, 123(3-5):133-139.
[53] PONS D G, NADAL-SERRANO M, BLANQUER-ROSSELLO M M, et al. Genistein modulates proliferation and mitochondrial functionality in breast cancer cells depending on ERalpha/ERbeta ratio[J]. J Cell Biochem, 2014, 115(5):949-958.
[54] PONS D G, NADAL-SERRANO M, TORRENS-MAS M, et al. The phytoestrogen genistein affects breast cancer cells treatment depending on the ERα/ERβ ratio[J]. J Cell Biochem, 2016, 117(1):218-229.
[55] JAZBUTYTE V, KEHL F, NEYSES L, et al. Estrogen receptor alpha interacts with 17beta-hydroxysteroid dehydrogenase type 10 in mitochondria[J]. Biochem Biophys Res Commun, 2009, 384(4):450-454.
[56] PEDRAM A, RAZANDI M, WALLACE D C, et al. Functional estrogen receptors in the mitochondria of breast cancer cells[J]. Mol Biol Cell, 2006, 17(5):2125-2137.
[57] SIMPKINS J W, YANG S H, SARKAR S N, et al. Estrogen actions on mitochondria-physiological and pathological implications[J]. Mol Cell Endocrinol, 2008, 290(1-2):51-59.
[58] LAGRANHA C J, DESCHAMPS A, APONTE A, et al. Sex differences in the phosphorylation of mitochondrial proteins result in reduced production of reactive oxygen species and cardioprotection in females[J]. Circ Res, 2010, 106(11):1681-1691.
[59] COLOM B, OLIVER J, ROCA P, et al. Caloric restriction and gender modulate cardiac muscle mitochondrial H2O2 production and oxidative damage[J]. Cardiovasc Res, 2007, 74(3):456-465.
[60] STIRONE C, DUCKLES S P, KRAUSE D N, et al. Estrogen increases mitochondrial efficiency and reduces oxidative stress in cerebral blood vessels[J]. Mol Pharmacol, 2005, 68(4):959-965.
[61] RAZMARA A, DUCKLES S P, KRAUSE D N, et al. Estrogen suppresses brain mitochondrial oxidative stress in female and male rats[J]. Brain Res, 2007, 1176:71-81.
[62] CHEN Y, ZHANG Z, HU F, et al. 17β-estradiol prevents cardiac diastolic dysfunction by stimulating mitochondrial function:a preclinical study in a mouse model of a human hypertrophic cardiomyopathy mutation[J]. J Steroid Biochem Mol Biol, 2015, 147:92-102.
[63] MENAZZA S, MURPHY E.The expanding complexity of estrogen receptor signaling in the cardiovascular system[J]. Circ Res, 2016, 118(6):994-1007.
[64] CHAMBLISS K L, WU Q, OLTMANN S, et al. Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice[J]. J Clin Invest, 2010, 120(7):2319-2330.
[65] SPENCE R D, VOSKUHL R R.Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration[J]. Front Neuroendocrinol, 2012, 33(1):105-115.
[66] VEGETO E, BONINCONTRO C, POLLIO G, et al. Estrogen prevents the lipopolysaccharide-induced inflammatory response in microglia [J]. J Neurosci, 2001, 21(6):1809-1818.
[67] LANG T J.Estrogen as an immunomodulator[J]. Clin Immunol, 2004, 113(3):224-230.
[68] GHISLETTI S, MEDA C, MAGGI A, et al. 17beta-estradiol inhibits inflammatory gene expression by controlling NF-kappaB intracellular localization[J]. Mol Cell Biol, 2005, 25(8):2957-2968.
[69] GAVIN K M, SEALS D R, SILVER A E, et al. Vascular endothelial estrogen receptor alpha is modulated by estrogen status and related to endothelial function and endothelial nitric oxide synthase in healthy women[J]. J Clin Endocrinol Metab, 2009, 94(9):3513-3520.
[70] TAMIR S, IZRAEL S, VAYA J.The effect of oxidative stress on ERalpha and ERbeta expression[J]. J Steroid Biochem Mol Biol, 2002, 81(4-5):327-332.
[71] IHIONKHAN C E, CHAMBLISS K L, GIBSON L L, et al. Estrogen causes dynamic alterations in endothelial estrogen receptor expression[J]. Circ Res, 2002, 91(9):814-820.
[72] MEHTA A, TRIPATHY D.Co-targeting estrogen receptor and HER2 pathways in breast cancer[J]. Breast, 2014, 23(1):2-9.
[73] ANDÒ S, PANNO M L, SALERNO M, et al. Role of IRS-1 signaling in insulin-induced modulation of estrogen receptors in breast cancer cells[J]. Biochem Biophys Res Commun, 1998, 253(2):315-319.
[74] GIANFREDI V, VANNINI S, MORETTI M, et al. Sulforaphane and epigallocatechin gallate restore estrogen receptor expression by modulating epigenetic events in the breast cancer cell line MDA-MB-231:a systematic review and Meta-analysis[J]. J Nutrigenet Nutrigenomics, 2017, 10(3-4):126-135. |
